Treatment of Lateral Medullary Syndrome in Acute Ischemic Stroke
In acute ischemic stroke presenting as lateral medullary syndrome, treatment eligibility and time from symptom onset are central to clinical decision-making. This protocol addresses the criteria and approach for selected patients requiring rapid intervention.
Treatment Approach
Intravenous rtPA is part of the recommended approach for eligible patients treated within a defined window from stroke onset. The full protocol specifies the patient selection criteria, timing thresholds, and administration parameters — only a portion of this regimen is outlined here.
References
DOI: 10.1161/STR.0b013e318284056a
- Intravenous rtPA (0.9 mg/kg, maximum dose 90 mg) is recommended for selected patients who may be treated within 3 hours of onset of ischemic stroke (Class I; Level of Evidence A).
- Intravenous rtPA (0.9 mg/kg, maximum dose 90 mg) is recommended for administration to eligible patients who can be treated in the time period of 3 to 4.5 hours after stroke onset (Class I; Level of Evidence B).
- Infuse 0.9 mg/kg (maximum dose 90 mg) over 60 minutes, with 10% of the dose given as a bolus over 1 minute.
View source ↗